Future Proofing & Incentives Among Industry Priorities In EU Pharma Law Shake Up
Executive Summary
Overhaul of the pharmaceutical legislation in the EU is an opportunity to learn from COVID-19, says European industry body.
You may also be interested in...
European Payers Target Marketing Exclusivity For Orphan Regulation Reform
European payers are calling for changes to the EU’s orphan drug rules that would transform the incentives system and avoid the market distortions enabled by the current legislation.
Expanding Hospital Exemptions For ATMPs Could Make Europe Less Attractive To Investors
The forthcoming overhaul of the EU pharma legislation should not include an expansion of the hospital exemption provision for advanced therapies, warn industry and regulators.
EU Pharma Legislation Overhaul To Lower IP Protection, Warns Industry
European Commission plans for an overhaul of the pharmaceutical legislation would halve market protection for orphan drugs and risk the predictability of the regulatory system, warns industry expert.